T. Christopher Bond
About T. Christopher Bond
T. Christopher Bond is the Senior Director of Pharmacoepidemiology and Immunoscience Lead at Bristol Myers Squibb, with extensive experience in epidemiology and a strong commitment to patient safety and public health.
Title and Role at Bristol Myers Squibb
T. Christopher Bond is currently serving as the Senior Director, Pharmacoepidemiology, and Immunoscience Lead at Bristol Myers Squibb. He operates out of Princeton, NJ, where he has led the Pharmacoepidemiology team since December 2018. In this role, he focuses on ensuring patient safety and the public health through the development and administration of Risk Evaluation and Mitigation Strategies (REMS), which include Elements to Assure Safe Use (ETASU). Bond collaborates closely with patient physicians to assess and manage patient access to investigational medicines, aiming to ensure that these medicines are distributed fairly and without compromising broader development programs.
Previous Experience in Pharmaceutical Companies
Prior to his current role at Bristol Myers Squibb, T. Christopher Bond accumulated extensive experience in epidemiology and pharmacoepidemiology at several prominent pharmaceutical and research organizations. From 2016 to 2018, he worked as Associate Director, Epidemiology at Purdue Pharma. Before that, Bond served as Senior Manager, Epidemiology at Covance from 2012 to 2016. Additionally, he held the position of Manager/Senior Manager, Epidemiology at DaVita Clinical Research from 2010 to 2012. These roles have collectively contributed to his comprehensive expertise in benefit-risk assessment, data visualization, pharmacovigilance, and evidence-based medicine.
Education and Academic Background
T. Christopher Bond has a robust academic background with multiple advanced degrees in fields relevant to his current work. He earned his PhD in Epidemiology from Emory University, where he studied from 2005 to 2010. Before that, Bond achieved both MA and PhD degrees in English Language and Literature from the University of Notre Dame. His foundational education includes a BA in Biology and English from La Salle University. This diverse academic journey has equipped him with a unique interdisciplinary perspective that he brings to his role in pharmacoepidemiology and public health.
Contributions to Industry Initiatives
T. Christopher Bond has contributed significantly to various industry initiatives and projects aimed at improving drug safety and patient care. One notable project is the IQ Consortium Drug-Induced Liver Injury Initiative (iqdili.org), where he has played an active role. Another significant involvement is with the IMI-ConcePTION project (imi-conception.eu), which focuses on ensuring the safety of medications for specific populations. His work emphasizes the principles of enhanced transparency and clinical trial data sharing, reflecting his commitment to patient safety and evidence-based practices.
Specialized Expertise and Commitment
Specializing in benefit-risk assessment, RWE analytics, pharmacovigilance, and comparative effectiveness research, T. Christopher Bond brings a wealth of expertise to his current role. His efforts are centered on ensuring that investigational medicines are accessible without compromising scientific integrity or regulatory requisites. Bond supports the development of bioequivalent generic drugs, tiered pricing strategies for medicine accessibility in regions with high disease impact, and programs designed to elevate patient awareness and improve access to treatment. His dedication to patient safety and public health underlines his work, echoing his belief in the transformative power of medicines in clinical care and life quality.